Astellas Bets on Newer Drug Portfolio to Power Profit Growth Through 2030

Astellas Pharma (ALPMY) is counting on high-margin treatments including cancer therapy Padcev and eye drug Izervay to hit a five-year target of at least ¥4.3 trillion ($27 billion) in cumulative core operating profit before research and development costs.

The Japanese drugmaker said Tuesday that its strategic brands are on track to double revenues by fiscal 2030, rising from ¥480 billion in fiscal 2025, with pipeline sales projected to reach roughly ¥1 trillion by the mid-2030s.

The targets reflect Astellas's effort to reduce its dependence on blockbuster prostate cancer treatment Xtandi, which it co-markets with Pfizer (PFE) and which faces mounting pressure from generic competition in the coming years. To bolster its development pipeline, the Tokyo-based company plans to initiate more than 10 Phase 3 or pivotal clinical studies before fiscal 2030.

On capital returns, Astellas committed to raising its annual dividend by at least ¥2 per year and pledged to direct a minimum of ¥750 billion toward shareholder returns over the five-year period.